Lantheus Holdings, Inc. (NASDAQ:LNTH) is expected to report third quarter earnings results, before market open, on Thursday 5th November 2020.
Analysts polled by Thomson Reuters anticipate third quarter income of $ 0.01 per share.
Looking ahead, the full year income are expected at $ 0.47 per share on the revenues of $ 347.97 million.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 384.00 million ~ $ 390.00 million, where as bottomline are predicted in a range of $ 1.34 ~ $ 1.40 per share
Click Here For More Historical Outlooks Of Lantheus Holdings, Inc.
Previous Quarter Performance
Lantheus Holdings, Inc. outlined income for the second quarter of $ 0.10 per share, from the revenue of $ 66.01 million. The quarterly earnings declined 62.96 percent compared with the same quarter last year. Street analysts expected Lantheus Holdings, Inc. to report income of $ 0.06 per share on revenue of $ 57.40 million for the second quarter. The bottom line results beat street analysts by $ 0.04 or 66.67 percent, at the same time, top line results outshined analysts by $ 8.61 million or 15.00 percent.
Stock Performance
Shares of Lantheus Holdings, Inc. traded up $ 0.18 or 1.63 percent on Wednesday, reaching $ 11.24 with volume of 460.10 thousand shares. Lantheus Holdings, Inc. has traded high as $ 11.37 and has cracked $ 10.97 on the downward trend
The closing price of $ 11.24, representing a 27.57 % increase from the 52 week low of $ 8.67 and a 49.36 % decrease over the 52 week high of $ 21.84.
The company has a market capital of $ 750.98 million and is part of the Healthcare sector and Diagnostics & Research industry.
Conference Call
Lantheus Holdings, Inc. will be hosting a conference call at 8:00 AM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.lantheus.com
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures.
